Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis - Summary - MDSpire

Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis

  • By

  • Haixia Zhang

  • Jiaqiang Hu

  • Yaxi Jiang

  • Lihua Deng

  • Song Liu

  • June 16, 2026

  • 0 min

Share

Objective:

To compare the efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes (LR-MDS) across multiple clinical endpoints.

Approach:
    Key Findings:
    • Clarify the context and significance of the findings.
    Interpretation:

    Remove unsupported conclusions about individualized treatment approaches.

    Limitations:
    • Add specificity regarding the implications of the limitations.
    Conclusion:

    Remove unsupported claims about treatment approaches.

    Sources:

Original Source(s)

Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis

  • by Haixia Zhang, Jiaqiang Hu, Yaxi Jiang, Lihua Deng, Song Liu

  • June 16, 2026

Related Content

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

Approximately 3% to 4% of the population over the age of 50 is diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It carries a lifelong risk of progression to multiple myeloma and lymphoma, requiring risk-adapted monitoring by multidisciplinary teams.

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia